STOCK TITAN

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Heron Therapeutics, Inc. (HRTX) will host an Investor Day in New York City on May 15, 2024, focusing on Acute Care and Oncology franchises. The event will feature presentations on company initiatives, patient and physician experiences, and a live webcast.
Positive
  • None.
Negative
  • None.

SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET. The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and Oncology franchises and panel discussions featuring patient and physician experience with Heron's commercial products. The presentations will also include updates on several ongoing initiatives in the Acute Care franchise to expand reach and adoption. 

The event will include a live webcast which will be archived and available for replay after the event. Please visit the "Investors" section of the Company website at Investor Resources - Heron Therapeutics (herontx.com) to register for the webcast and for additional information on the event.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400

(PRNewsfoto/Heron Therapeutics, Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-host-investor-day-on-may-15-2024-in-new-york-city-302114792.html

SOURCE Heron Therapeutics, Inc.

Heron Therapeutics will host the Investor Day on Wednesday, May 15, 2024, in New York City.

The Investor Day will focus on the Acute Care and Oncology franchises of Heron Therapeutics.

Yes, the event will include presentations from the Company's leadership team.

Yes, there will be a live webcast of the event, which will be archived for replay.

To register for the webcast and get more information, visit the 'Investors' section of the Heron Therapeutics website.
Heron Therapeutics, Inc.

NASDAQ:HRTX

HRTX Rankings

HRTX Latest News

HRTX Stock Data

375.82M
122.02M
0.93%
76.01%
17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About HRTX

heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.